AUG血型抗原研究进展
|
摘要
<正>Augustine(简称AUG)抗原是ISBT在2016年新确认的"系统"抗原,该系统有2个抗原,其中AUG2是原来的"系列"中的高频抗原Ata。2016年国际输血协会(ISBT)把AUG1和AUG2重新划入系统抗原,编号036,系统名AUG。AUG抗
The Augustine antigen(referred to as AUG)is a newly recognized "system" antigen for ISBT in2016,and the system has 2 antigens,in which AUG2 is the high frequency antigen Ata in the original "series".In2016,the international blood transfusion Association(ISBT)re classified AUG1 and AUG2 into the system antigen,numbered 036,and the system name AUG.AUG antigen is nucleoside transporter 1(ENT1),also known as the " AUG glycoprotein",is a member of nucleoside transporter family,involved in the synthesis of intracellular DNA and RNA,is also an important link of chemotherapy drugs into the tumor cells of glycoside.
The Augustine antigen(referred to as AUG)is a newly recognized "system" antigen for ISBT in2016,and the system has 2 antigens,in which AUG2 is the high frequency antigen Ata in the original "series".In2016,the international blood transfusion Association(ISBT)re classified AUG1 and AUG2 into the system antigen,numbered 036,and the system name AUG.AUG antigen is nucleoside transporter 1(ENT1),also known as the " AUG glycoprotein",is a member of nucleoside transporter family,involved in the synthesis of intracellular DNA and RNA,is also an important link of chemotherapy drugs into the tumor cells of glycoside.
引文
[1]Baloch K,Chen L,Memon AA,et al.Equilibrative nucleoside transporter 1expression in primary human hepatocytes is highly variable and determines uptake of ribavirin[J].Antivir Chem Chemother,2017,25:2-10.
[2]Giovannetti E,Leon LG,Gómez VE,et al.A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells,and modulated the expression of the human equilibrative transporter-1[J].Nucleosides Nucleotides Nucleic Acids,2016,35:643-651.
[3]Zafar M,Naydenova Z.Extended exposure to substrate regulates the human equilibrative nucleoside transporter 1(hENT1)[J].Nucleosides Nucleotides Nucleic Acids,2016,35:631.
[4]Damaraju VL,Weber D,Kuzma M,et al.Selective Inhibition of Human Equilibrative and Concentrative Nucleoside Transporters by BCR-ABL Kinase Inhibitors:IDENTIFICATION OF KEY hENT1 AMINOACID RESIDUES FOR INTERACTION WITHBCR-ABL KINASE INHIBITORS[J].J Biol Chem,2016,291:18809-18817.
[5]Wu L,Shi W,Li X,et al.High expression of the human equilibrative nucleoside transporter 1gene predicts a good response to decitabine in patients with myelodysplastic syndrome[J].J Transl Med,2016,14:66.
[6]Yamada R,Mizuno S,Uchida K,et al.Human Equilibrative Nucleoside Transporter 1Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Clinical Response and Survival in the Patients With Pancreatic Ductal Adenocarcinoma Undergoing GemcitabineBased Chemoradiotherapy[J].Pancreas,2016,45:761-771.
[7]Panigrahi R,Dash S.ENT1and treatment of viral diseases[J].Oncotarget,2015,6:32281-32282.
[8]Aseervatham J,Tran L,Machaca K,et al.The role of flexible loops in folding,trafficking and activity of equilibrative nucleoside transporters[J].PLoS One,2015,10:e0136779.
[9]Wan H,Zhu J,Chen F,et al.SLC29A1single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia:an in vitro study[J].J Exp Clin Cancer Res,2014,33:90.
[10]Tavano F,Fontana A,Pellegrini F,et al.Modeling interactions between Human Equilibrative Nucleoside Transporter-1and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients[J].J Transl Med,2014,12:248.
[11]Sinn M,Riess H,Sinn BV,et al.Human equilibrative nucleoside transporter 1expression analysed by the clone SP 120rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine-result from the CONKO-001trial[J].Eur J Cancer,2015,51:1546-1554.
[12]Zhu Y,Qi M,Lao L,et al.Human equilibrative nucleoside transporter 1predicts survival in patients with pancreatic cancer treated with gemcitabine:a meta-analysis[J].Genet Test Mol Biomarkers,2014,18:306-312.
[13]Furihata T,Mizuguchi M,Suzuki Y,et al.Identification of primary equilibrative nucleoside transporter 1mRNA isoforms resulting from alternative promoter usage in human hepatocytes[J].Drug Metab Pharmacokinet,2014,29:325-332.
[14]Liu ZQ,Han YC,Zhang X,et al.Prognostic value of human equilibrative nucleoside transporter1in pancreatic cancer receiving gemcitabin-based chemotherapy:a meta-analysis[J].PLoS One,2014,9:e87103.
[15]Mohelnikova-Duchonova B,Melichar B.Human equilibrative nucleoside transporter 1(hENT1):do we really have a new predictive biomarker of chemotherapy outcome in pancreatic cancer patients?[J].Pancreatology,2013,13:558-563.
[16]Wei CH,Gorgan TR,Elashoff DA,et al.A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers[J].Pancreas,2013,42:1303-1310.
[17]Suzuki Y,Homma M,Abei M,et al.Impact of solute carrier family 29 member 1(SLC29A1)single nucleotide polymorphisms on mRNA expression in peripheral blood mononuclear cells[J].Biol Pharm Bull,2013,36:144-146.
[18]Plotnik DA,Asher C,Chu SK,et al.Levels of human equilibrative nucleoside transporter-1 are higher in proliferating regions of A549tumor cells grown as tumor xenografts in vivo[J].Nucl Med Biol,2012,39:1161-1166.
[19]Park JS,Hammond JR.Cysteine residues in the transmembrane(TM)9to TM11region of the human equilibrative nucleoside transporter subtype 1play an important role in inhibitor binding and translocation function[J].Mol Pharmacol,2012,82:784-794.
[20]Shan D,Haroutunian V,Meador-Woodruff JH,et al.Expression of equilibrative nucleoside transporter type1protein in elderly patients with schizophrenia[J].Neuroreport,2012,23:224-227.
[21]Tsubota A,Shimada N,Yoshizawa K,et al.Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1bpatients[J].Liver Int,2012,32:826-836.
[22]Murata Y,Hamada T,Kishiwada M,et al.Human equilibrative nucleoside transporter 1expression is a strong independent prognostic factor in UICC T3-T4pancreatic cancer patients treated with preoperative gemcitabine-basedchemoradiotherapy[J].J Hepatobiliary Pancreat Sci,2012,19:413-425.
[23]Borbath I,Verbrugghe L,Lai R,et al.Human equilibrative nucleoside transporter 1(hENT1)expression is apotential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma[J].Eur J Cancer,2012,48:990-996.
[24]Yao SY,Ng AM,Cass CE,et al.Nucleobase transport by human equilibrative nucleoside transporter 1(hENT1)[J].J Biol Chem,2011,286:32552-32562.
[25]Rehan S,Jaakola VP.Expression,purification and functional characterization of human equilibrative nucleoside transporter subtype-1(hENT1)protein from Sf9insect cells[J].Protein Expr Purif,2015,114:99-107.
[26]李树中,卞洁,徐姿,等.Junier血型系统[J].临床血液学杂志(输血与检验),2014,27(10):913-915.
[27]卞洁,李树中,李凌波,等.一个新的血型抗原-Langereis血型系统[J].临床血液学(输血与检验),2015,28(12):1096-1100.
[28]方莹,李树中.forssman血型系统[J].临床血液学杂志(输血与检验),2016,29(2):171-174.
[29]徐姿,李树中,卞洁,等.红细胞血型抗原的研究进展[J].临床血液学杂志(输血与检验),2016,29(4):345-350.
[2]Giovannetti E,Leon LG,Gómez VE,et al.A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells,and modulated the expression of the human equilibrative transporter-1[J].Nucleosides Nucleotides Nucleic Acids,2016,35:643-651.
[3]Zafar M,Naydenova Z.Extended exposure to substrate regulates the human equilibrative nucleoside transporter 1(hENT1)[J].Nucleosides Nucleotides Nucleic Acids,2016,35:631.
[4]Damaraju VL,Weber D,Kuzma M,et al.Selective Inhibition of Human Equilibrative and Concentrative Nucleoside Transporters by BCR-ABL Kinase Inhibitors:IDENTIFICATION OF KEY hENT1 AMINOACID RESIDUES FOR INTERACTION WITHBCR-ABL KINASE INHIBITORS[J].J Biol Chem,2016,291:18809-18817.
[5]Wu L,Shi W,Li X,et al.High expression of the human equilibrative nucleoside transporter 1gene predicts a good response to decitabine in patients with myelodysplastic syndrome[J].J Transl Med,2016,14:66.
[6]Yamada R,Mizuno S,Uchida K,et al.Human Equilibrative Nucleoside Transporter 1Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Clinical Response and Survival in the Patients With Pancreatic Ductal Adenocarcinoma Undergoing GemcitabineBased Chemoradiotherapy[J].Pancreas,2016,45:761-771.
[7]Panigrahi R,Dash S.ENT1and treatment of viral diseases[J].Oncotarget,2015,6:32281-32282.
[8]Aseervatham J,Tran L,Machaca K,et al.The role of flexible loops in folding,trafficking and activity of equilibrative nucleoside transporters[J].PLoS One,2015,10:e0136779.
[9]Wan H,Zhu J,Chen F,et al.SLC29A1single nucleotide polymorphisms as independent prognostic predictors for survival of patients with acute myeloid leukemia:an in vitro study[J].J Exp Clin Cancer Res,2014,33:90.
[10]Tavano F,Fontana A,Pellegrini F,et al.Modeling interactions between Human Equilibrative Nucleoside Transporter-1and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients[J].J Transl Med,2014,12:248.
[11]Sinn M,Riess H,Sinn BV,et al.Human equilibrative nucleoside transporter 1expression analysed by the clone SP 120rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine-result from the CONKO-001trial[J].Eur J Cancer,2015,51:1546-1554.
[12]Zhu Y,Qi M,Lao L,et al.Human equilibrative nucleoside transporter 1predicts survival in patients with pancreatic cancer treated with gemcitabine:a meta-analysis[J].Genet Test Mol Biomarkers,2014,18:306-312.
[13]Furihata T,Mizuguchi M,Suzuki Y,et al.Identification of primary equilibrative nucleoside transporter 1mRNA isoforms resulting from alternative promoter usage in human hepatocytes[J].Drug Metab Pharmacokinet,2014,29:325-332.
[14]Liu ZQ,Han YC,Zhang X,et al.Prognostic value of human equilibrative nucleoside transporter1in pancreatic cancer receiving gemcitabin-based chemotherapy:a meta-analysis[J].PLoS One,2014,9:e87103.
[15]Mohelnikova-Duchonova B,Melichar B.Human equilibrative nucleoside transporter 1(hENT1):do we really have a new predictive biomarker of chemotherapy outcome in pancreatic cancer patients?[J].Pancreatology,2013,13:558-563.
[16]Wei CH,Gorgan TR,Elashoff DA,et al.A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers[J].Pancreas,2013,42:1303-1310.
[17]Suzuki Y,Homma M,Abei M,et al.Impact of solute carrier family 29 member 1(SLC29A1)single nucleotide polymorphisms on mRNA expression in peripheral blood mononuclear cells[J].Biol Pharm Bull,2013,36:144-146.
[18]Plotnik DA,Asher C,Chu SK,et al.Levels of human equilibrative nucleoside transporter-1 are higher in proliferating regions of A549tumor cells grown as tumor xenografts in vivo[J].Nucl Med Biol,2012,39:1161-1166.
[19]Park JS,Hammond JR.Cysteine residues in the transmembrane(TM)9to TM11region of the human equilibrative nucleoside transporter subtype 1play an important role in inhibitor binding and translocation function[J].Mol Pharmacol,2012,82:784-794.
[20]Shan D,Haroutunian V,Meador-Woodruff JH,et al.Expression of equilibrative nucleoside transporter type1protein in elderly patients with schizophrenia[J].Neuroreport,2012,23:224-227.
[21]Tsubota A,Shimada N,Yoshizawa K,et al.Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1bpatients[J].Liver Int,2012,32:826-836.
[22]Murata Y,Hamada T,Kishiwada M,et al.Human equilibrative nucleoside transporter 1expression is a strong independent prognostic factor in UICC T3-T4pancreatic cancer patients treated with preoperative gemcitabine-basedchemoradiotherapy[J].J Hepatobiliary Pancreat Sci,2012,19:413-425.
[23]Borbath I,Verbrugghe L,Lai R,et al.Human equilibrative nucleoside transporter 1(hENT1)expression is apotential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma[J].Eur J Cancer,2012,48:990-996.
[24]Yao SY,Ng AM,Cass CE,et al.Nucleobase transport by human equilibrative nucleoside transporter 1(hENT1)[J].J Biol Chem,2011,286:32552-32562.
[25]Rehan S,Jaakola VP.Expression,purification and functional characterization of human equilibrative nucleoside transporter subtype-1(hENT1)protein from Sf9insect cells[J].Protein Expr Purif,2015,114:99-107.
[26]李树中,卞洁,徐姿,等.Junier血型系统[J].临床血液学杂志(输血与检验),2014,27(10):913-915.
[27]卞洁,李树中,李凌波,等.一个新的血型抗原-Langereis血型系统[J].临床血液学(输血与检验),2015,28(12):1096-1100.
[28]方莹,李树中.forssman血型系统[J].临床血液学杂志(输血与检验),2016,29(2):171-174.
[29]徐姿,李树中,卞洁,等.红细胞血型抗原的研究进展[J].临床血液学杂志(输血与检验),2016,29(4):345-350.